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Somatic cellular reprogramming is a fast-paced and evolving field that is changing the way scientists
approach neurological diseases. For the first time in the history of neuroscience, it is feasible to study the
behavior of live neurons from patients with neurodegenerative diseases, such as Alzheimer’s and Parkin-
son’s disease, and neuropsychiatric diseases, such as autism and schizophrenia. In this Perspective, we
will discuss reprogramming technology in the context of its potential use for modeling and treating neurolog-
ical and psychiatric diseases and will highlight areas of caution and opportunities for improvement.Introduction
Widespread use of reprogramming and programming technol-
ogy is challenging our view of differentiated cells as irreversible
entities. From the early works of Briggs and King (Briggs and
King, 1952) and Gurdon (Gurdon et al., 1958) to the widespread
advent of induced pluripotent stem cells (iPSCs) by Takahashi
and Yamanaka (Takahashi and Yamanaka, 2006; Takahashi
et al., 2007; Yamanaka, 2012), we are now faced with the
remarkable idea that all cells in our body maintain an intrinsic
plasticity for differentiating into a variety of cell types with
completely different functions. The impact of this technology
has been most strongly felt in the neurosciences. While much
work remains to be done to improve and refine the technology,
attempts to apply these techniques to the clinic are already
underway. One could argue that it is too early to consider trans-
lational research because much more basic understanding of its
implications is required, but some of the applied approaches are
pushing the field forward, resulting in the need for better system-
atic safety and reliability standards. Undoubtedly, much more
work is needed to optimize iPSC technology. In this Perspective,
we will discuss reprogramming technologies and their potential
uses for modeling and treating neurological and psychiatric dis-
eases, as well as highlighting areas of caution and opportunities
for improvement.
Modeling Neurological and Psychiatric Diseases In Vitro
with Pluripotent Stem Cells
Neurological and Psychiatric Diseases Currently Being
Modeled with Patient-Derived iPSCs
Soon after human cells were first reprogrammed (Takahashi
et al., 2007), a number of groups used the technology to model
neurodevelopmental and neurodegenerative diseases. Neuro-
genetic disorders were modeled first (Dimos et al., 2008; Lee
et al., 2009; Marchetto et al., 2010; Zhang et al., 2010), followed
by a few examples of sporadic and complex disorders (e.g.,
schizophrenia [SCHZ] [Brennand et al., 2011; Paulsen et al.,
2012; Pedrosa et al., 2011]), providing important insights into
disease biology and potential therapeutic avenues (see Table 1
for references, description of diseases, and rescuing drugs).
From these studies of neurodevelopmental/neuropsychiatric
diseases, a general pattern has emerged regarding the inability678 Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc.of neurons to establish proper connections. Specifically, inade-
quate neuronal maturation, synaptic deficiency, and failed con-
nectivity have been observed in many of the early-onset and
neurodevelopmental diseases modeled so far (examples:
familial dysautonomia [FD] [Lee et al., 2009], Rett syndrome
[RTT] [Marchetto et al., 2010; Ricciardi et al., 2012], Huntington’s
disease [HD] [Chae et al., 2012], SCHZ [Brennand et al., 2011]).
On the other hand, human iPSCs from patients with neurodegen-
erative disorders, while considered to be suitable for modeling
neurodegenerative disorders, do not always exhibit the neuronal
maturation and network defects that are observed in vivo. It is
possible that this apparent identification of synaptic deficits
may be in part because these are the measurements that have
been focused on so far. In neurodegenerative diseases and pro-
teopathies, neuronal toxicity due to increased sensitivity to
oxidative damage and proteasome inhibition seems to be more
prevalent than strictly synaptic deficits. Examples of these dis-
eases include amyotrophic lateral sclerosis (ALS) (Mitne-Neto
et al., 2011), Parkinson’s disease (PD) (Nguyen et al., 2011),
Alzheimer’s disease (AD) (Israel et al., 2012), and Down syn-
drome, which mimics some aspects of AD (Shi et al., 2012). As
the number of patients and types of neurological diseases being
modeled increases, new patterns will emerge that could aid in
the development of earlier diagnostic tools and facilitate effec-
tive drug design. Significant interest is growing among clinicians
and the pharmaceutical industries as additional neurological
conditions are proposed to be modeled using iPSCs. Attractive
candidate diseases include, but are not restricted to, major
depression, migraine, attention deficit hyperactivity disorder
(ADHD), and idiopathic autism.
Major Challenges in Modeling Neurological and
Psychiatric Disease and Tools for Addressing Them
When developing in vitro models, the main goal is to establish a
meaningful parallel between the phenotypes observed in the
dish and the disease pathology observed in vivo. An important
set of challenges that currently surround this field involve the
variability between clones and changes in clone genome and
phenotype over passage and time. Targeted genome modifica-
tion of human pluripotent cells using engineered constructs
like zinc-finger nucleases (ZFNs) (Kim et al., 1996; Porteus
2010), transcription activator-like effector nucleases (TALENs)
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clustered regularly interspaced palindromic repeats/CRISPR-
associated (CRISPR/Cas) system (Wiedenheft et al., 2012; Mali
et al., 2013) present promising strategies to model monogenic
and genetically defined disorders with reduced variability by
generating isogenic control lines harboring defined genetic alter-
ations (Soldner et al., 2011). These techniques are discussed in
detail by Merkle and Eggan (2013) in this issue. However, these
approaches are of limited use for modeling sporadic cases of
diseases or complex neuropsychiatric disorders where there is
no clear genetic etiology. It is conceivable that identifying proto-
cols that generate lineage-specific cells will solve this problem
by allowing investigators to monitor the differentiation process
more specifically. Defining and consistently obtaining the dis-
ease-relevant neural cells at comparable levels of maturation
should greatly reduce the phenotypical variability and highlight
pertinent disease characteristics. Assessing neuronal network
connectivity formation is important for understanding neuronal
communication imbalance in disease but it can be a challenging
task because as a general rule the right subtype of neurons and
the specific maturation time are not represented in the dish at
appropriate levels. To that end, promoter-bashing technology
may aid in generating the desired populations of neurons that
are directly involved in the disease being studied (for example,
Hb9-positive cells for disease involving alpha motor neurons
such as ALS [Dimos et al., 2008; Mitne-Neto et al., 2011] or
TH-positive dopaminergic neurons for PD [Devine et al., 2011;
Nguyen et al., 2011; Jiang et al., 2012; Peng et al., 2013]). Addi-
tionally, single-cell expression profiling should further clarify the
levels of population heterogeneity within in vitro cultures, and
advances in media culture platforms and automated cell pro-
cessing should provide the desired accuracy and consistency
that will be required.
For a number of neurological diseases, it remains unclear
whether the phenotypes involved in the pathology are restricted
to the neuronal population and to what extent the neighboring
cells are also playing a major role. Improving the protocols for
generation of cells present in the neuronal niche (i.e., astrocytes,
oligodendrocytes, microglia, endothelial cells) could reveal
important disease phenotypes and contribute to the develop-
ment of alternative therapies. Refining the techniques to analyze
neuronal phenotypes will also help to detect more subtle differ-
ences. Examples of techniques that have not been widely
explored for neuronal characterization are light-activated chan-
nelrhodopsins, uncaged glutamate, transynaptic labeling using
virus or dyes, multielectrode arrays, spine motility, high-resolu-
tion electron microscopy, axon protein transport dynamics,
organelle activity and mobilization, and microfluidics devices
for cellular compartmentalization. The field is becoming interdis-
ciplinary, bringing together technological advancements from
multiple areas including electrical and mechanical engineering
with principles of neuroscience and stem cell biology. In the
following sections, we briefly discuss two laboratory-on-a-chip
technologies, microfluidics and microelectrode arrays (MEA),
that have the potential to assist researchers in achieving these
goals.
Finally, we posit that many of the challenges to in vitro disease
modeling arise from the overall strategy employed. Many of the
current disease modeling studies search for differences ingene expression generally or for basic functions that can be
measured in vitro that have been hypothesized to be correlated
causally in the disease. Often these studies are not hypothesis
driven but rather depend on existing techniques and the avail-
ability of somatic cells from whatever patients are available to
the researcher. However, researchers are increasingly working
more closely with the clinicians who attend to and treat patients
with the diseases to better understand the diversity of each of
the patient populations to be studied and to obtain more
restricted populations of patients (e.g., discordant monozygotic
twins, drug-responsive versus nonresponsive cohorts, severity
degrees of the disease). These kinds of collaborations between
bench and bedside may not only lead to more targeted hypoth-
eses but may also assist in decreasing the variability reported for
in vitro modeling.
Improving Culture Conditions to BetterMimic the In Vivo
Environment
While two-dimensional cell cultures have been fundamental to
cell biology, drug discovery, and tissue engineering, they are
unable to fully recapitulate the complex and dynamic three-
dimensional (3D) environment of the tissue in vivo. Microfluidics
technology allows an engineered platform for 3D cell culture with
complex and dynamic microenvironments that are controllable
and reproducible. Current approaches to reducing the variability
in iPSC-disease models often utilize multiple iPSC clones
derived from select cohorts of patients. Microfluidic devices
fabricated from oxygen-permeable material such as polydime-
thylsiloxane (PDMS) can support long-term neural cultures while
occupying less space and using significantly fewer reagents than
traditional tissue-culture techniques, making it feasible to
conduct experiments involving a large number of iPSC lines for
disease modeling and drug screening. The microscale dimen-
sions of the microchannel designs are comparable to in vivo
cytoarchitectural features and can create multiple chemical
gradients to simulate endogenous in vivo auto- and paracrine
signaling cues. iPSC-based disease models have just begun to
fully explore the possibilities offered by this technology. An inter-
esting study demonstrating the precision and control of these
devices differentiated human embryonic stem cells (hESCs) as
embryoid bodies (EBs) on a Y channel device and was able to
induce differentiation on half of a single EB while simultaneously
maintaining the other half in an uninduced state (Fung et al.,
2009). Similarly, maintenance of hESC self-renewal and differen-
tiation can be manipulated at the single-colony level (Villa-Diaz
et al., 2009).
In addition, micropatterning using biomaterials (i.e., collagen,
laminin) combined with fabrication of physical structures allows
for the isolation of dendrites and axons as well as compartmen-
talization of cellular subtypes to create highly organized struc-
tures that can mimic the organization of the endogenous tissue
or organ (Figure 1). A study using 3D micropatterned neuronal
cultures showed that chemical gradients of nerve growth factor
(NGF) and the serum substitute, B27, could orient the direction of
neurite outgrowth and regulate synapse distribution (Kunze
et al., 2011a, 2011b). And finally, microfluidic platforms can inte-
grate cell culture with subsequent cell-based assays such as
genetic and protein analysis on a single device, providing a ver-
satile tool for accurate quantification of biometrics that can be
adapted for high-throughput, high-content screening.Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc. 679
Table 1. Neurological Syndromes for which iPSCs Have Been Derived
Disease Genetic Defect Neurological Symptoms
Phenotype in hiPSC-Derived Neural
Progeny
Therapeutic Approach:
Genetic Manipulation or Drug Reference
Adrenoleukodystrophy ABCD1 Demyelination and central
and peripheric nervous
system progressive loss
of function
Very long chain fatty acid level was
increased in oligodendrocytes
Lovastatin, 4-phenylbutyrate (Jang et al., 2011)
Alzheimer’s disease (AD) Multifactorial or PS1,
PS2, APP duplication
Progressive memory disorientation
and impaired cognition
Increased amyloid b (Ab) secretion,
increased phospho-tau (Thrc231) and
active glycogen synthase kinase-3b
(aGSK-3b)
g-secretase inhibitor decreased
(Ab) secretion
b-secretase inhibitors reduced
phospho-Tau (Thrc231) and
aGSK-3b levels
(Yagi et al., 2011;
Israel et al., 2012)
Amyotrophic lateral
sclerosis (ALS)
SOD1, VAPB, TDP43 Neuromuscular degeneration and
progressive loss of upper and lower
motor neurons, causing weakness
and paralysis
VAPB: reduced levels of VAPB in
motor neurons derived from patients
with VAPB mutation
TDP43: mutant neurons had elevated
levels of soluble and detergent-
resistant TDP-43 protein, decreased
survival in longitudinal studies, and
increased vulnerability to antagonism
of the PI3K pathway
N/A (Dimos et al., 2008;
Mitne-Neto et al., 2011;
Egawa et al., 2012)
Huntington’s disease (HD) CAG repeat expansion
in Huntingtin gene (HTT)
Progressive chorea and dementia
associated with loss of striatal
medium spiny neurons and cortical
neurons
HD-neural stem cells showed
susceptibility stress; vulnerability to
BDNF withdrawn, increased cell
death and altered mitochondria
bioenergetics. Formation of protein
aggregate inclusions after treatment
with proteasome inhibitor (MG132).
Vacuolation in HD-astrocytes.
Increase in lysosomal activity in
HD-iPS cells
Genetic correction by
homologous recombination
(Zhang et al., 2010;
An et al., 2012;
Camnasio et al., 2012;
Chae et al., 2012;
HD iPSC Consortium,
2012)
Familial dysautonomia (FD) IKBKAP Degeneration of sensory and
autonomic neurons
Decreased expression of genes
involved in neurogenesis and
neuronal differentiation; defects
in neural crest migration
Kinetin (Lee et al., 2009)
Parkinson’s disease (PD) LRRK2, PINK1, SNCA
and Parkin
Age-related degeneration of both
central and peripheral nervous
systems
Impaired mitochondrial function in
PINK1-mutated dopaminergic
neurons; sensitivity to oxidative stress
in LRRK2 and SNCA-mutant neurons.
Reduced dopamine reuptake and
increase of spontaneous dopamine
release
N/A (Devine et al., 2011;
Nguyen et al., 2011;
Seibler et al., 2011;
Jiang et al., 2012;
Peng et al., 2013)
(Continued on next page)
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Table 1. Continued
Disease Genetic Defect Neurological Symptoms
Phenotype in hiPSC-Derived Neural
Progeny
Therapeutic Approach:
Genetic Manipulation or Drug Reference
Ret yndrome (RTT) MeCP2
CDKL5
Large spectrum of autistic
characteristics, impaired motor
function, regression of developmental
skills, hypotonia, seizures; atypical
Rett syndrome has clinical features
closely related to Rett syndrome,
including intellectual disability, early-
onset intractable epilepsy starting
before the age of 6 months, and
autism
MeCP2: neuronal maturation defects,
decreased synapse number, reduced
number of spines, smaller cell soma
size, and elevated LINE1
retrotransposition
CDKL5: aberrant dendritic spines
Insulin growth factor 1(IGF1),
gentamicin
(Marchetto et al., 2010;
Muotri et al., 2010;
Ananiev et al., 2011;
Koch et al., 2011;
Ricciardi et al., 2012;
Weinacht et al., 2012)
Sch ophrenia Multifactorial Neuropsychiatric disease
characterized by hallucinations,
delusions, and disorganized speech.
Pathological hallmarks involve
aberrant neurotransmitter signaling,
reduced dendritic arborization, and
impaired myelination
Diminished neuronal connectivity
and decreased neurite number,
PSD95 and glutamate receptor
expression. Increase in
extramitochondrial oxygen
consumption and elevated levels
of reactive oxygen species (ROS)
Loxapine,
valporic acid
(Brennand et al., 2011;
Paulsen et al., 2012;
Pedrosa et al., 2011)
Spi l muscular atrophy
(SM )
SMN1 Selective loss of lower motor neurons
resulting in muscle weakness and
paralysis
Reduced size and number of
SMA-mutant motor neurons
Valporic acid, tobramycin (Ebert et al., 2009)
Tim hy syndrome CACNA1C Long-QT syndrome
Neurological defects, autistic
characteristics
Decreased expression of genes
that are expressed in lower cortical
layers and in callosal projection
neurons, abnormal expression of
tyrosine hydroxylase and increased
production of norepinephrine and
dopamine, activity-dependent
dendritic retraction
Roscovitine
Expression of RGK protein, Gem.
(Pasxca et al., 2011;
Yazawa et al., 2011)
Mac ado-Joseph Disease MJD1 (ATXN3) Dominantly inherited late-onset
neurodegenerative disorder caused
by expansion of polyglutamine
(polyQ)-encoding CAG repeats in the
MJD1 gene
Excitation-induced ataxin-3
aggregation in differentiated
neurons
Elimination of SDS-insoluble
fraction by Calpain inhibitors
(ALLN, calpeptin)
(Koch et al., 2011)
DO N syndrome (DS) Trisomy 21 Mental delay, early-onset Alzheimer’s
disease
Cortical neurons develop AD
pathologies: secretion of the
pathogenic peptide fragment
amyloid-b42 (Ab42) and formation
of insoluble amyloid aggregates.
Presence of hyperphosphorylated tau
protein on cell bodies and dendrites
g-secretase inhibitor
decreased (Ab) secretion
(Park et al., 2008;
Shi et al., 2012)
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Figure 1. Proposed Use of Microfluidic
Chambers for Proper Reproduction of
Hippocampal Circuitry
Mircropatterning using biomaterials combined
with of bioengineered cell chambers allow for
isolation of dendrite and axons as well as
compartmentalization of cellular subtypes to
create highly organized structures that can mimic
the organization of the endogenous tissue.
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PerspectiveWhile engineering platforms allow the researcher precision and
control over the cellular microenvironment, in vivo transplanta-
tion of stem cell-derived populations of human pluripotent
stem cells (hPSCs) and neurons into animal models presents a
useful way to study human development and model disease.
Grafting the neural progenitor cells (NPCs) at appropriate devel-
opmental stages could potentially utilize the myriad biochemical
and biophysical cues provided in the endogenous niches to
generate mature and functional populations of the desired cells.
An excellent example is the transplantation of hPSC-derived
forebrain NPCs into the neonatal mouse brain to generate
cortical neurons with specific axonal projections and dendritic
patterns corresponding to the native cortical neuron population
(Espuny-Camacho et al., 2013). These transplanted human
cortical neurons showed progressive differentiation and connec-
tivity over several months in vivo, demonstrating that these cells
can develop properties characteristic of developmental cortico-
genesis and may offer opportunities for modeling of human cor-
tex diseases and brain repair. In addition, transplantation of
hPSC-derived medial ganglionic eminence (MGE) progenitors
into the rodent brain produced GABAergic interneurons with
mature physiological properties along an intrinsic timeline that
mimics the endogenous human neural development (Maroof
et al., 2013; Nicholas et al., 2013). AsMGE-derived cortical inter-
neuron deficiencies are implicated in a number of neurodevelop-
ment and degenerative disorders, this technique may be used to
model human neural development and disease. Finally, another
still controversial alternative would be the use of human-mouse
chimeras generated from hESC engraftment to mouse blasto-
cysts (Siqueira da Fonseca et al., 2009); however, the extent to
which these cells recapitulate human development remains to
be determined.
Characterizing Neuronal Connectivity and Network
Properties
A unique function of the nervous system is its dependence on
properties that emerge from the networks of neurons and glia682 Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc.cells. While much research had been
done looking at the cellular properties of
its individual constituents (neurons or
glia), we are just beginning to formulate
the tools that would allow us to examine
the emergent properties of these com-
plex neural networks (Power et al.,
2011). It is clear that neurodegenerative
and psychiatric disorders, while exhibit-
ing disease attributes at the single-cell
level, are also manifestations of alter-
ations in structure and function at the
network level (Seeley et al., 2007; Churchet al., 2009; Seeley et al., 2009). Recent work using iPSCs for
disease modeling also demonstrated that there might be signif-
icant defects in the connectivity of neuronal networks of patients
with autism and schizophrenia (Marchetto et al., 2010; Brennand
et al., 2011). Substrate-integrated microelectrode arrays (MEAs)
fabricated with semiconductor-based techniques can be a use-
ful tool to further investigate the connectivity of functional neural
networks. These platforms have been demonstrated to support
long-term neuronal culture (Musick et al., 2009) and can be com-
bined with microfluidics designs to record activity between
distinct populations of neurons (Kanagasabapathi et al., 2011).
Thus far in the field of iPSC research, MEAs have been mostly
used with iPSC-derived cardiomyocytes to measure extracel-
lular field potentials and has been combined with imaging
modalities (i.e., intracellular calcium) to provide information
about electrical coupling and action potential propagation
between cells (Lee et al., 2012a).
The application of MEAs in neuroscience has been limited in
part by the fact that, while it can simultaneously record multiple
neurons and observe them over long periods of time, MEAs can
only measure extracellular field potentials and cannot replace
the full electrophysiological repertoire (subthreshold synaptic
potentials, membrane oscillations, fast-spiking action potentials,
etc.) offered by traditional intracellular recordings. However,
recent advances in MEA technology are moving toward designs
that can provide intracellular recording in addition to the tradi-
tional substrate-integrated MEA platforms. One promising
design is the gold mushroom-shaped microelectrodes (gMmEs),
which are shaped tomimic the dendritic spine and functionalized
with extracelluar matrix (ECM) binding domains to facilitate
endocytosis and cytoskeletal rearrangement around the micro-
electrode. Individual gMmEs can monitor action potentials
(APs) and subthreshold synaptic potentials; they can also evoke
APs without damaging the cell (Hai et al., 2010a, 2010b). In
addition, silicon nanowires fabricated as the gate electrode of
field-effect transistors (FET) and coated with phospholipids
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membrane and perform intracellular recordings of APs (Tian
et al., 2010; Duan et al., 2012). While the long-term stability
and modalities of these designs have to be further validated in
primary and stem cell-derived neurons, they present very
exciting possibilities for future developments in the iPSC field
as tools in basic scientific research and drug discovery.
Translational and Clinical Opportunities for Pluripotent
Stem Cells
Stem Cell-Based Platforms for Drug Discovery
While regeneration of diseased tissue to restore function remains
the holy grail of stem cell therapy, a more immediate therapeutic
role for iPSCs may be as a platform for drug discovery. Develop-
ment of new drugs is an expensive and time-consuming process
where90%of drug candidates fail at clinical trials due to issues
of safety and efficacy. Preclinical studies largely based on cell
lines and animal models are limited by their inability to fully reca-
pitulate normal cellular function, the lack of disease-relevant
functional assays, and interspecies differences in biological
pathways as well as pharmacokinetic properties. iPSCs offer a
number of advantages over the traditional methods. Disease-
specific iPSCs can provide a renewable source of human cells
with genetic background sensitive to disease pathology. A num-
ber of these iPSC-based disease models have demonstrated
amelioration of disease phenotype in response to known thera-
peutic agents (Marchetto et al., 2010; Brennand et al., 2011;
Israel et al., 2012). Drug screening using these cellular models
could provide a more sensitive and accurate assessment of
the test compounds. A recent study used iPSCs-derived dopa-
minergic neurons to screen a group of compounds for neuropro-
tective properties as a treatment strategy for early stages of PD.
Of the 44 compounds that demonstrated therapeutic effects in
rodent systems, only 16 provided significant neuroprotection in
the rotenone-induced dopaminergic neuron cell death model
for PD, emphasizing the importance of using disease-relevant
human neurons for these assays (Peng et al., 2013). An in-depth
discussion of using human pluoripotent stem cells to build more
physiologically relevant in vitro assays for drug development is
presented by Engle and Puppala (2013) in this issue.
Work is underway to develop high-throughput screening (HTS)
assay systems to evaluate small molecule therapy for CNS dis-
eases using iPSCs. To scale up from validating a few com-
pounds to screening large chemical libraries, some key issues
must be addressed. Aside from large-scale production of the
disease-relevant cell types, it is critical to define relevant pheno-
types suitable for automated HTS assays. Common modalities
used for high-throughput platforms include imaging-based
assessment of cell viability and function as well as quantification
of gene expression and protein levels. A recent study reported
screening 6,912 small molecule compounds on neural crest pre-
cursors derived from familial dysautonomia (FD) patient iPSCs.
The authors employed a tiered approach that first detected
rescued levels of wt-IKBKAP, the gene responsible for FD, with
qPCR-PCR, then followed up the eight hit compounds with
further validation in additional iPSC clones as well as using
immune blots and migration assays (Lee et al., 2012b). While
these results are promising, findings from iPSC-based disease
models for a number of CNS diseases have also identifiedmore complex phenotypes such as connectivity and synaptic
defects (see sections on iPSC disease models); the challenge
remains to formulate strategies to screen for these attributes in
a high-throughput format.
Finally, iPSCs may also be used to assess developmental as
well as cell-type-specific drug toxicities. Indeed, there are
already commercially available hiPSC-derived hepatocytes,
cardiomyocytes, and neural cells that may provide the basis
for humanized assays to detect off-target activity and side-
effects of drugs in a tissue-specific manner (Scott et al., 2013).
By incorporating relevant functional assessments such as drug
transporter activity in iPSC-generated hepatocytes, beating pro-
files of cardiomyocytes, and synaptic activity of neurons, one
might unveil toxicity pathways that could not be observed in pre-
vious cellular models and improve the safety profiles of candi-
date drugs during their preclinical development.
Pluripotent Stem Cells for Transplantation Therapies
Stem cell therapy has been explored in clinical trials since the
late 1980s using human fetal neural stem cell (fNSC) transplanta-
tion for a variety of CNS disorders including PD (Lindvall et al.,
1990; Isacson et al., 2003; Lindvall and Bjo¨rklund 2004; Mendez
et al., 2005), HD (Philpott et al., 1997; Freeman et al., 2000;
Bachoud-Le´vi et al., 2006), and ALS (Glass et al., 2012), in which
a phase I study to assess intraspinal injection of fNSCs has been
recently initiated. However, results from these clinical studies
have varied greatly between patients. While there were a few
sporadic cases of improvements in cognitive and/or motor func-
tions following the transplant procedures (Bachoud-Le´vi et al.,
2006), it remains largely unclear whether the benefits of these
transplant therapies outweigh the risks associated with the
requisite surgical procedures and the graft-induced complica-
tions. Among other concerns, the limited availability of fetal tis-
sue presents a major challenge in standardizing the cells used
for these transplant procedures. This limitation not only contrib-
utes to the variability of the outcomes, but also complicates the
interpretation of these study results. Human ESCs and iPSCs
can potentially circumvent these difficulties by providing a
renewable source of disease-relevant cells to serve as an alter-
native to fetal neural tissue for transplantation. Here, we will
focus on the recent developments and findings using human
ESC- and iPSC-derived cells for transplantation in clinical
therapeutics.
Clinical Studies Using hESC and iPSCs
Although it has been only seven years since the introduction of
somatic reprogramming technology to generate iPSCs, there
are already clinical studies underway for bringing iPSC-based
cell therapy to patients. The Takahashi group at the RIKEN
Center for Developmental Biology in Kobe, Japan, is proposing
to treat a cohort of six patients with severe age-related macular
degeneration (AMD), a condition where deterioration of photore-
ceptors results in vision loss in the central visual field, by using
cells derived from patient-specific iPSCs. Takahashi, who
previously reported the differentiation of ESCs and iPSCs to
functioning rod photoreceptors (Homma et al., 2013), plans to
transplant sheets of iPSC-derived retinal cells into the subretinal
space of AMD patients to rescue and restore the pigmented
epithelium. A similar study using hESCs was published last
year, where two patients (one with dry age-related macular
degeneration and one with Stargardt’s macular dystrophy)Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc. 683
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epithelium (RPE) cells into the subretinal space of each patient’s
eye (Schwartz et al., 2012). No hyperproliferation, abnormal
growth, or immune-mediated transplant rejection was observed
in either patient at 4months after the surgeries. The investigators
reported anatomical evidence of hESC-derived RPE survival and
engraftment in the patient with Stargardt’s macular dystrophy by
spectral domain ocular coherence tomography and improve-
ment in visual acuity from hand motions to counting fingers at
postoperative week 2. The AMD patient also demonstrated
some visual improvement from 20/500 at baseline to 20/320 by
week 6, although there were also mild functional increases in
the fellow eye, confounding this result.
Takahashi’s current study, less tightly regulated than a formal
clinical trial by the Japanese Ministry of Health and Welfare,
cannot by itself lead to approval of a treatment for clinical use.
However, if approved, it will be the first clinical demonstration
of iPSCs for medical use and will, without doubt, impact the
outlook regarding the safety and efficacy of iPSC-based cell
therapy.
Immunogenicity of iPSCs and Related Challenges for
Extending iPSCs to Clinical Use
Despite the promise of iPSCs as an autologous cell source for
transplant therapy that would theoretically mitigate host immune
rejection of the grafted cells, the immunogenicity of iPSCs is still
a controversial topic. The controversy was sparked by a study in
2011 that reported an unexpected immune reaction triggered by
teratomas generated from syngeneic iPSCs. A significantly
higher rejection rate was reported with the iPSC-derived versus
ESC-derived teratoma and was linked to aberrant expression of
a number of tumor-related genes including Hormad1 and Zb16
(Zhao et al., 2011). Two recent reports have challenged these
findings, showing that terminally differentiated cell types (endo-
thelial cells, hepatocytes, and neurons) did not induce T cell re-
sponses either in culture or after tissue engraftment (Guha et al.,
2013). Moreover, there wasminimal immune reaction against the
teratoma tissue derived from syngeneic iPSCs established using
integration-freemethods (Araki et al., 2013). It is conceivable that
differences in the vector choice used for reprogramming in these
studies, i.e., retroviral-, lentiviral-, and integration-free plasmids,
may have contributed to the immunogenicity differences
observed in the subsequent iPSC lines (Kaneko and Yamanaka,
2013). However, more importantly, these studies highlight how
much is still unknown regarding the basic biology of reprogram-
ming technology, knowledge that will be critical for iPSCs to be
safely used in clinical settings. Which method should be consid-
ered the reprogramming vector of choice to generate clinical-
grade iPSC lines? Should each patient-derived iPSC line be
individually assessed for its tumorigenicity as well as its effi-
ciency of producing the disease-relevant cell type needed for
the treatment? How will the cost and labor needed for quality
control impact the feasibility of establishing iPSCs as a standard-
ized therapy? In an effort to address the safety concerns
regarding iPSCs in clinical use, the biotechnology firm
Advanced Cell Technology (ACT), in Santa Monica, California,
is applying for FDA approval for a less ambitious clinical trial
of injecting hiPSC-derived platelets as a potential treatment
of coagulopathies (http://www.ipscell.com/2012/12/advanced-
cell-technology-actc-announces-plan-to-make-ips-cell-derived-684 Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc.platelets-some-thoughts/). Platelets, lacking a nucleus, would
reduce the risks for tumors and tumor-associated immune
responses. But the challenge remains: for iPSC cell therapy to
be applicable in the clinical setting, much more groundwork is
needed to better understand the biology of these reprogrammed
cells and their progenies.
Bridging Bench to Bedside
To successfully advance hESC- and iPSC-based cell therapy to
clinical trials, a number of additional special considerations
remain to be addressed. Developing clear benchmarks for
assessing these issues in the preclinical stages will greatly
facilitate the evaluation and interpretation of outcomes in future
clinical trials.
Despite promising evidence of differentiation, maturation, and
integration of the grafted cells into the endogenous neural cir-
cuitry in animal models (Lu et al., 2012; Ma et al., 2012; Nicholas
et al., 2013), cells used for transplantation must be rigorously
assessed for their proliferation potential as well as their fidelity
in generating the desired cell type. Finding accurate biomarkers
for cell sorting or engineering regulated suicide genes for induc-
ible apoptosismay provide ways to select for the desired cells for
use in transplantation. Targeted selection of the desired cells not
only would reduce the risk of tumorgenesis in vivo, but would
also allow more accurate formulation of the optimal cell dosage
for the intended therapy and identify optimal treatment windows
for clinical studies. In addition, while a number of preclinical
studies have demonstrated functional improvement after trans-
plantation of hESC- and hiPSC-derived neurons in animals
models (Roy et al., 2006; Wernig et al., 2008; Hargus et al.,
2010; Jiang et al., 2011; Lu et al., 2012; Ma et al., 2012), the
mechanisms of the recovery, whether it is due to reconstruction
of damaged neural circuitry or neurotrophic support, remain un-
clear. Elucidating the precisemechanisms of functional recovery
is critical for designing human trials, specifically for the determi-
nation of the best time course for follow-ups after the procedure
and the methods of evaluation for therapeutic efficacy, both of
which will maximize knowledge gained from these trials.
Furthermore, a critical factor for the success of hematopoietic
stem cell transplantation, the only stem cell-based therapy glob-
ally accepted in the clinical setting, is the intrinsic ability of
hematopoietic stem cells to home to the bone marrow. The
mobility and migration potential of hESC/hiPSCs and their prog-
enies have yet to be assessed in detail in vivo. The ability of trans-
planted cells to target the sites of disease and injury will greatly
impact the types of conditions that are suitable for hESC/hiPSC-
based cell therapy and will affect the surgical methods for deliv-
ering the transplants. Finally, the efficacy of hESC/hiPSC cell
therapy should be compared with the current gold standard
of treatment for the disease. Patients can have higher risk-
tolerance toward experimental medicine; therefore, evidence
of superior performance should be reproducibly established
prior to movement into human trials.
In Vivo Reprogramming in Human Subjects
An attractive alternative to cell-replacement therapy would be to
mobilize resident cells already present in the target tissue to
repair the damage. One possibility would be to use on-site
reprogramming technology to generate specific subtypes of
cells that have been lost through aging, injury, or disease.
A few successful attempts have been made to reprogram (or
Figure 2. Potential Applications of
Reprogramming Technology in the Clinical
Setting for Neurological Diseases
Promising approaches include better under-
standing of disease biology, development of new
diagnostic tools, formulation of new therapies, and
personalized clinical interventions.
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Perspectivetransdifferentiate) cells in the rodent central nervous system
by ectopically expressing region-specific transcription factors
(Jessberger et al., 2008; Lo´pez-Bendito and Arlotta, 2012). In a
recent study, transplanted human fibroblasts and human astro-
cytes engineered to express inducible forms of neural reprog-
ramming genes (complex-like 1 [Ascl1], brain-2 [Brn2a], and
myelin transcription factor-like 1 [Myt1l] converted into neurons
after activation of these genes in vivo. Additionally, endogenous
astrocytes in a transgenic mouse model with directed expres-
sion of these reprogramming genes to the parenchymal astro-
cytes in the striatum can be directly converted into neural nuclei
(NeuN)-expressing neurons in situ (Torper et al., 2013).
There are currently a number of obstacles to be overcome
before in vivo reprogramming in the nervous system becomes
an accepted therapy for human neural pathology. Themain chal-
lenges are identifying the cell types that are able to be reprog-
rammed in vivo and optimizing the methods of specific delivery
of the reprogramming vehicle. Defining and targeting the best
cell type in the nervous system will require basic knowledge of
brain niche biology and dynamics. Examples of this work are un-
derway but it will be critical to determine that reprogrammed
cells are not only functional in vivo, but also are appropriately
functional for the target areas or damaged circuit. This will
require functional studies that demonstrate reprogramming
and functional recovery and confirmation that the recovery
depends on the reprogrammed cells. The replacement of the
exact cell that is lost through disease or damage may not be
necessary; it would be impressive enough that the reprog-
rammed substitution or compensatory mechanism caused func-
tional recovery. In vivo reprogramming technology in the nervous
system has the potential to become an important tool for gener-Cell Stem Ceating significant therapies that are patient
tailored, but a lot of fundamental research
remains to be performed.
Conclusion/Future directions
Reprogramming technology has resulted
in fundamental changes in how we think
about cell biology, stimulating a rapid
movement to clinical and commercial
applications (Figure 2). We present here
our perspective on this movement, sug-
gesting that there are many positive
developments that can occur. For
modeling human disease and HTS using
hPSCs, the risks are that the high
variability in the methods and relative
paucity of lineage-specific differentiation
protocols may limit our ability to mimic
or detect disease-specific phenotypicchanges. The good news is that, with appropriate cell banking,
iPSCs can allow multiple attempts on the same cohorts for
discovery and screening. It is also encouraging to consider the
engineering, chemistry, and material science advances that
can be applied to optimize these in vitro studies.
The in vivo applications for cell replacement and endogenous
reprogramming are still at very early stages of development.
However, in some instances, thoughtful attempts at cell therapy
using reprogramming technology are underway. Of course, the
risk here is that failure will have greater consequences. Other
cutting-edge areas, such as gene therapy, have suffered
tremendously from just a single poorly implemented clinical trial.
Even more disturbing is the current extent of unsubstantiated
stem cell therapy offerings with little or no evidence for claims
of efficacy. There is a need for concerted efforts to regulate
stem cell clinical offerings by unscrupulous commercial enter-
prises globally. To this end, it is important to support the best
and most carefully designed clinical studies, setting the bar
high for what is expected for a successful clinical trial outcome.REFERENCES
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